Recent Content
- The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma
- Exploring the role of circulating proteins in multiple myeloma risk: a Mendelian randomization study
- Targeting ABCD1-ACOX1-MET/IGF1R axis suppresses multiple myeloma
- EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destruction
- A 30-Minute Infusion of Isatuximab Is Safe, Feasible in Patients with Newly Diagnosed Multiple Myeloma
- Efficacy and safety of anti-CD38 monoclonal antibodies-based therapy versus standard therapy in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis
- PCMMD: A Novel Dataset of Plasma Cells to Support the Diagnosis of Multiple Myeloma
- International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma
- Navigating the Challenges of Bispecific Antibodies in Relapsed and Refractory Multiple Myeloma
- The association between the dietary inflammatory index and multiple myeloma: a case–control study